A phase I trial of MK-2206 and hydroxychloroquine in solid tumors, melanoma, renal and prostate cancer to examine the role of autophagy in tumorigenesis
Latest Information Update: 15 Mar 2024
At a glance
- Drugs MK 2206 (Primary) ; Hydroxychloroquine
- Indications Colon cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- 30 Dec 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Mar 2020.
- 24 May 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 15 May 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2018.